Table 5 Characteristic of AML patients treatment in validation cohort
Variable | UBE2E1 high | UBE2E1 low | p |
|---|---|---|---|
Treatment, no.(%) | 25(100) | 25(100) | 0.422 |
CAG | 2(8) | 1(4) | |
DA | 9(36) | 11(44) | |
QA | 1(4) | 0 | |
HAD | 1(4) | 0 | |
IDA | 6(24) | 11(44) | |
D-CAG | 2(8) | 1(4) | |
Allo-HSCT | 0(0) | 0(0) |
Variable | UBE2E1 high | UBE2E1 low | p |
|---|---|---|---|
Treatment, no.(%) | 25(100) | 25(100) | 0.422 |
CAG | 2(8) | 1(4) | |
DA | 9(36) | 11(44) | |
QA | 1(4) | 0 | |
HAD | 1(4) | 0 | |
IDA | 6(24) | 11(44) | |
D-CAG | 2(8) | 1(4) | |
Allo-HSCT | 0(0) | 0(0) |